BioSpace News Archive

Catamaran Bio, Inc. today announced the formation of its scientific advisory board (SAB).

Aptose Biosciences Inc. will report financial results for the quarter ended September 30, 2021, and provide a corporate update on Thursday, November 11, 2021, after the close of the market.

Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2021 financial results on Monday, November 8, 2021 , and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

Marinus Pharmaceuticals, Inc. today announced plans to release financial results for the third quarter ended September 30, 2021 before the market opens on November 9, 2021.

Cybin Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the Company’s sponsored feasibility study using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.

9 Meters Biopharma, Inc. today presented pharmacokinetic data on its drug candidate vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in development for short bowel syndrome (SBS), at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting, being held in Las Vegas, Nevada through October 27, 2021.

Evaxion Biotech A/S announced today that it has filed a registration statement on Form F-1 (the “Registration Statement) with the U.S. Securities and Exchange Commission (the “SEC”)

BioNTech SE announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022.

eFFECTOR Therapeutics today announced that management will participate in and host 1x1 meetings at the following upcoming investor conferences